Vitality Watch

Dossier pubmed preclinical 18-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.

Key claim: Cellular senescence markers appear early in motor cortex and spinal cord of TDP-43 ALS mice, and senolytic dasatinib plus quercetin improves motor behavior, neuromuscular function, reduces plasma neurofilament light chain, and preserves layer V neurons.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration in the motor cortex and spinal cord. Aging is a key risk factor for ALS, and cellular senescence - a hallmark of aging marked by irreversible cell-cycle arrest and a pro-inflammatory senescence-associated secretory phenotype - has been implicated in neurodegeneration, yet its role in ALS progression remains incompletely understood. Here, we show that molecular markers of cellular senescence emerge in the motor cortex and spinal cord alongside declines in neural and neuromuscular function in TDP-43ALS mice, supporting senescence as an early feature of ALS pathology. To test whether reduced senescence ameliorates ALS pathology, we evaluated longitudinal senolytic treatment with dasatinib and quercetin (D&Q) in TDP-43mice. D&Q treatment improved motor behavior, neuromuscular function, and reduced axonal damage as measured by plasma neurofilament light chain, accompanied by robust improvements in motor cortex excitability and preservation of layer V neuron counts. At the cellular level, cortical microglia were implicated as a potential mediator of senolytic benefits based on reduced microglial TDP-43 burden and senescence markers. Together, these findings identify cellular senescence as an early, disease-relevant, and modifiable feature of ALS pathology.

Why this matters

ALS has largely been framed around TDP-43 proteinopathy and motor-neuron-intrinsic degeneration; this study reframes cellular senescence as an early, causal contributor in the motor cortex and spinal cord rather than a bystander, and shows the canonical D+Q senolytic can move motor, neuromuscular, and blood-biomarker (NfL) outcomes in a TDP-43 mouse. It extends the growing tissue-specific senolytics map into motor neuron disease and adds another indication where the senolytic thesis is being tested preclinically before any human ALS translation.

Source

Link

Briefing card

Cellular senescence is an early feature and therapeutic target in amyotrophic lateral sclerosis TDP-43mice.
Stage: preclinical · pubmed · 18-sep-2026

If you follow senolytic research, ALS TDP-43 mice now join the list of preclinical models where dasatinib+quercetin showed functional benefit — no human ALS outcome data yet.

Cellular senescence markers appear early in motor cortex and spinal cord of TDP-43 ALS mice, and senolytic dasatinib plus quercetin improves motor behavior, neuromuscular function, reduces plasma neurofilament light chain, and preserves layer V neurons.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.nbd.2026.107610

build build 880 · 2bcef25 · 2026-11-18